{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T11:29:59Z","timestamp":1794050999803,"version":"4.8.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T00:00:00Z","timestamp":1699833600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["AI169768"],"award-info":[{"award-number":["AI169768"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R37AI039394"],"award-info":[{"award-number":["R37AI039394"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U54AI170791"],"award-info":[{"award-number":["U54AI170791"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007301","name":"Harvard University Center for AIDS Research","doi-asserted-by":"publisher","award":["AI060354"],"award-info":[{"award-number":["AI060354"]}],"id":[{"id":"10.13039\/100007301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI106701"],"award-info":[{"award-number":["AI106701"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI164560"],"award-info":[{"award-number":["AI164560"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["AI154421"],"award-info":[{"award-number":["AI154421"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"name":"supported by a Scholar Award from Michael Smith Health Research BC","id":[{"id":"https:\/\/ror.org\/020x39229","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Burroughs Wellcome Career Award for Medical Scientists"},{"name":"This Research was supported in part by the Intramural Research Program of the NIH, Frederick National Lab, Center for Cancer Research","id":[{"id":"https:\/\/ror.org\/05bjen692","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Non-suppressible HIV-1 viremia (NSV) is defined as persistent low-level viremia on antiretroviral therapy (ART) without evidence of ART non-adherence or significant drug resistance. Unraveling the mechanisms behind NSV would broaden our understanding of HIV-1 persistence. Here we analyzed plasma virus sequences in eight ART-treated individuals with NSV (88% male) and show that they are composed of large clones without evidence of viral evolution over time in those with longitudinal samples. We defined proviruses that match plasma HIV-1 RNA sequences as \u2018producer proviruses\u2019, and those that did not as \u2018non-producer proviruses\u2019. Non-suppressible viremia arose from expanded clones of producer proviruses that were significantly larger than the genome-intact proviral reservoir of ART-suppressed individuals. Integration sites of producer proviruses were enriched in proximity to the activating H3K36me3 epigenetic mark. CD4\n                    <jats:sup>+<\/jats:sup>\n                    T cells from participants with NSV demonstrated upregulation of anti-apoptotic genes and downregulation of pro-apoptotic and type I\/II interferon-related pathways. Furthermore, participants with NSV showed significantly lower HIV-specific CD8\n                    <jats:sup>+<\/jats:sup>\n                    T cell responses compared with untreated viremic controllers with similar viral loads. We identified potential critical host and viral mediators of NSV that may represent targets to disrupt HIV-1 persistence.\n                  <\/jats:p>","DOI":"10.1038\/s41591-023-02611-1","type":"journal-article","created":{"date-parts":[[2023,11,13]],"date-time":"2023-11-13T12:02:08Z","timestamp":1699876928000},"page":"3212-3223","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["Viral and host mediators of non-suppressible HIV-1 viremia"],"prefix":"10.1038","volume":"29","author":[{"given":"Abbas","family":"Mohammadi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behzad","family":"Etemad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5300-0571","authenticated-orcid":false,"given":"Yijia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory J.","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radwa","family":"Sharaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Autumn","family":"Kittilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Melberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles R.","family":"Crain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Traunbauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colline","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0300-1255","authenticated-orcid":false,"given":"Jesse","family":"Fajnzylber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7760-9848","authenticated-orcid":false,"given":"Daniel P.","family":"Worrall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9154-2769","authenticated-orcid":false,"given":"Nikolaus","family":"Jilg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarety","family":"Kaseke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francoise","family":"Giguel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rinki","family":"Deo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rida","family":"Chishti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Abrha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Siagian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Dorazio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter L.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-747X","authenticated-orcid":false,"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Lederman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigal","family":"Yawetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel R.","family":"Kuritzkes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9865-8350","authenticated-orcid":false,"given":"Mathias D.","family":"Lichterfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1769-8682","authenticated-orcid":false,"given":"Scott","family":"Sieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2681-3216","authenticated-orcid":false,"given":"Athe","family":"Tsibris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2692-2180","authenticated-orcid":false,"given":"Mary","family":"Carrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zabrina L.","family":"Brumme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Castillo-Mancilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9709-2591","authenticated-orcid":false,"given":"Alan N.","family":"Engelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav D.","family":"Gaiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9914-9662","authenticated-orcid":false,"given":"Jonathan Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,13]]},"reference":[{"key":"2611_CR1","doi-asserted-by":"crossref","first-page":"5847","DOI":"10.1172\/JCI138099","volume":"130","author":"EK Halvas","year":"2020","unstructured":"Halvas, E. K. et al. HIV-1 viremia not suppressible by antiretroviral therapy can originate from large T cell clones producing infectious virus. J. Clin. Invest. 130, 5847\u20135857 (2020).","journal-title":"J. Clin. Invest."},{"key":"2611_CR2","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1093\/cid\/cit529","volume":"57","author":"C Laprise","year":"2013","unstructured":"Laprise, C., de Pokomandy, A., Baril, J. G., Dufresne, S. & Trottier, H. Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin. Infect. Dis. 57, 1489\u20131496 (2013).","journal-title":"Clin. Infect. Dis."},{"key":"2611_CR3","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1128\/AAC.00076-14","volume":"58","author":"P Ryscavage","year":"2014","unstructured":"Ryscavage, P., Kelly, S., Li, J. Z., Harrigan, P. R. & Taiwo, B. Significance and clinical management of persistent low-level viremia and very-low-level viremia in HIV-1-infected patients. Antimicrob. Agents Chemother. 58, 3585\u20133598 (2014).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2611_CR4","doi-asserted-by":"crossref","first-page":"ofaa346","DOI":"10.1093\/ofid\/ofaa346","volume":"7","author":"AD Redd","year":"2020","unstructured":"Redd, A. D. et al. ART adherence, resistance, and long-term HIV viral suppression in postpartum women. Open Forum Infect. Dis. 7, ofaa346 (2020).","journal-title":"Open Forum Infect. Dis."},{"key":"2611_CR5","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/S2352-3018(17)30063-2","volume":"4","author":"NJ Dharan","year":"2017","unstructured":"Dharan, N. J. & Cooper, D. A. Long-term durability of HIV viral load suppression. Lancet HIV 4, e279\u2013e280 (2017).","journal-title":"Lancet HIV"},{"key":"2611_CR6","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1097\/QAD.0000000000002306","volume":"33","author":"J Fleming","year":"2019","unstructured":"Fleming, J. et al. Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. AIDS 33, 2005\u20132012 (2019).","journal-title":"AIDS"},{"key":"2611_CR7","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1097\/QAD.0000000000002916","volume":"35","author":"AJ Prendergast","year":"2021","unstructured":"Prendergast, A. J. et al. The impact of viraemia on inflammatory biomarkers and CD4+ cell subpopulations in HIV-infected children in sub-Saharan Africa. AIDS 35, 1537\u20131548 (2021).","journal-title":"AIDS"},{"key":"2611_CR8","doi-asserted-by":"crossref","unstructured":"Castillo-Mancilla, J. R. et al. Low-Level Viremia Is Associated With Cumulative Adherence to Antiretroviral Therapy in Persons With HIV. Open Forum Infect. Dis. 8, ofab463 (2021).","DOI":"10.1093\/ofid\/ofab463"},{"key":"2611_CR9","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1128\/AAC.01217-12","volume":"56","author":"JZ Li","year":"2012","unstructured":"Li, J. Z. et al. Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob. Agents Chemother. 56, 5998\u20136000 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2611_CR10","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1128\/JVI.72.3.2422-2428.1998","volume":"72","author":"HF Gunthard","year":"1998","unstructured":"Gunthard, H. F. et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J. Virol. 72, 2422\u20132428 (1998).","journal-title":"J. Virol."},{"key":"2611_CR11","doi-asserted-by":"crossref","first-page":"10948","DOI":"10.1073\/pnas.97.20.10948","volume":"97","author":"J Martinez-Picado","year":"2000","unstructured":"Martinez-Picado, J. et al. Antiretroviral resistance during successful therapy of HIV type 1 infection. Proc. Natl Acad. Sci. USA 97, 10948\u201310953 (2000).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR12","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/cid\/ciac762","volume":"76","author":"O Elvstam","year":"2023","unstructured":"Elvstam, O. et al. Virologic failure following low-level viremia and viral blips during antiretroviral therapy: results from a European Multicenter Cohort. Clin. Infect. Dis. 76, 25\u201331 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"2611_CR13","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3851\/IMP2815","volume":"20","author":"N Boillat-Blanco","year":"2015","unstructured":"Boillat-Blanco, N. et al. Virological outcome and management of persistent low-level viraemia in HIV-1-infected patients: 11 years of the Swiss HIV Cohort Study. Antivir. Ther. 20, 165\u2013175 (2015).","journal-title":"Antivir. Ther."},{"key":"2611_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.virol.2017.07.010","volume":"510","author":"L Vancoillie","year":"2017","unstructured":"Vancoillie, L. et al. Longitudinal sequencing of HIV-1 infected patients with low-level viremia for years while on ART shows no indications for genetic evolution of the virus. Virology 510, 185\u2013193 (2017).","journal-title":"Virology"},{"key":"2611_CR15","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1086\/523704","volume":"196","author":"TJ Podsadecki","year":"2007","unstructured":"Podsadecki, T. J., Vrijens, B. C., Tousset, E. P., Rode, R. A. & Hanna, G. J. Decreased adherence to antiretroviral therapy observed prior to transient human immunodeficiency virus type 1 viremia. J. Infect. Dis. 196, 1773\u20131778 (2007).","journal-title":"J. Infect. Dis."},{"key":"2611_CR16","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jama.286.2.196","volume":"286","author":"M Hermankova","year":"2001","unstructured":"Hermankova, M. et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies\/ml receiving combination therapy. JAMA 286, 196\u2013207 (2001).","journal-title":"JAMA"},{"key":"2611_CR17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1001\/jama.286.2.171","volume":"286","author":"DV Havlir","year":"2001","unstructured":"Havlir, D. V. et al. Prevalence and predictive value of intermittent viremia with combination hiv therapy. JAMA 286, 171\u2013179 (2001).","journal-title":"JAMA"},{"key":"2611_CR18","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1097\/QAD.0000000000001824","volume":"32","author":"ME Bull","year":"2018","unstructured":"Bull, M. E. et al. Monotypic low-level HIV viremias during antiretroviral therapy are associated with disproportionate production of X4 virions and systemic immune activation. AIDS 32, 1389\u20131401 (2018).","journal-title":"AIDS"},{"key":"2611_CR19","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1093\/jac\/dkab062","volume":"76","author":"JZ Li","year":"2021","unstructured":"Li, J. Z. et al. Impact of pre-existing drug resistance on risk of virological failure in South Africa. J. Antimicrob. Chemother. 76, 1558\u20131563 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"2611_CR20","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/aid.2012.0089","volume":"29","author":"JR Castillo-Mancilla","year":"2013","unstructured":"Castillo-Mancilla, J. R. et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum. Retroviruses 29, 384\u2013390 (2013).","journal-title":"AIDS Res Hum. Retroviruses"},{"key":"2611_CR21","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/QAI.0000000000002354","volume":"84","author":"J Yager","year":"2020","unstructured":"Yager, J. et al. Intracellular tenofovir-diphosphate and emtricitabine-triphosphate in dried blood spots following tenofovir alafenamide: the TAF-DBS Study. J. Acquir Immune Defic. Syndr. 84, 323\u2013330 (2020).","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"2611_CR22","doi-asserted-by":"crossref","first-page":"6692","DOI":"10.1128\/AAC.01017-16","volume":"60","author":"J Castillo-Mancilla","year":"2016","unstructured":"Castillo-Mancilla, J. et al. Emtricitabine-triphosphate in dried blood spots as a marker of recent dosing. Antimicrob. Agents Chemother. 60, 6692\u20136697 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"2611_CR23","unstructured":"Coyle RP et al. Tenofovir diphosphate in dried blood spots in persons with HIV taking tenofovir alafenamide as digital pills: preliminary data from the QUANTI-TAF Study. In International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs. (2022)."},{"key":"2611_CR24","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1093\/jac\/dky559","volume":"74","author":"K Frasca","year":"2019","unstructured":"Frasca, K. et al. Emtricitabine triphosphate in dried blood spots is a predictor of viral suppression in HIV infection and reflects short-term adherence to antiretroviral therapy. J. Antimicrob. Chemother. 74, 1395\u20131401 (2019).","journal-title":"J. Antimicrob. Chemother."},{"key":"2611_CR25","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/infdis\/jiz144","volume":"220","author":"M Morrow","year":"2019","unstructured":"Morrow, M. et al. Predictive value of tenofovir diphosphate in dried blood spots for future viremia in persons living with HIV. J. Infect. Dis. 220, 635\u2013642 (2019).","journal-title":"J. Infect. Dis."},{"key":"2611_CR26","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1097\/QAD.0000000000002981","volume":"35","author":"M Morrow","year":"2021","unstructured":"Morrow, M. et al. Emtricitabine triphosphate in dried blood spots predicts future viremia in persons with HIV and identifies mismatch with self-reported adherence. AIDS 35, 1949\u20131956 (2021).","journal-title":"AIDS"},{"key":"2611_CR27","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/S0092-8674(02)00864-4","volume":"110","author":"AR Schroder","year":"2002","unstructured":"Schroder, A. R. et al. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 110, 521\u2013529 (2002).","journal-title":"Cell"},{"key":"2611_CR28","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1101\/gr.6286907","volume":"17","author":"GP Wang","year":"2007","unstructured":"Wang, G. P., Ciuffi, A., Leipzig, J., Berry, C. C. & Bushman, F. D. HIV integration site selection: analysis by massively parallel pyrosequencing reveals association with epigenetic modifications. Genome Res. 17, 1186\u20131194 (2007).","journal-title":"Genome Res."},{"key":"2611_CR29","volume":"11","author":"AC Francis","year":"2020","unstructured":"Francis, A. C. et al. HIV-1 replication complexes accumulate in nuclear speckles and integrate into speckle-associated genomic domains. Nat. Commun. 11, 3505 (2020).","journal-title":"Nat. Commun."},{"key":"2611_CR30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1126\/science.1254194","volume":"345","author":"F Maldarelli","year":"2014","unstructured":"Maldarelli, F. et al. HIV latency. Specific HIV integration sites are linked to clonal expansion and persistence of infected cells. Science 345, 179\u2013183 (2014).","journal-title":"Science"},{"key":"2611_CR31","first-page":"E2575","volume":"115","author":"Z Wang","year":"2018","unstructured":"Wang, Z. et al. Expanded cellular clones carrying replication-competent HIV-1 persist, wax, and wane. Proc. Natl Acad. Sci. USA 115, E2575\u2013E2584 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR32","doi-asserted-by":"crossref","first-page":"e145254","DOI":"10.1172\/JCI145254","volume":"131","author":"FR Simonetti","year":"2021","unstructured":"Simonetti, F. R. et al. Antigen-driven clonal selection shapes the persistence of HIV-1-infected CD4+ T cells in vivo. J. Clin. Invest. 131, e145254 (2021).","journal-title":"J. Clin. Invest."},{"key":"2611_CR33","doi-asserted-by":"crossref","first-page":"e1009141","DOI":"10.1371\/journal.ppat.1009141","volume":"17","author":"JM Coffin","year":"2021","unstructured":"Coffin, J. M. et al. Integration in oncogenes plays only a minor role in determining the in vivo distribution of HIV integration sites before or during suppressive antiretroviral therapy. PLoS Pathog. 17, e1009141 (2021).","journal-title":"PLoS Pathog."},{"key":"2611_CR34","doi-asserted-by":"crossref","first-page":"7330","DOI":"10.1093\/nar\/gkab514","volume":"49","author":"GJ Bedwell","year":"2021","unstructured":"Bedwell, G. J., Jang, S., Li, W., Singh, P. K. & Engelman, A. N. rigrag: high-resolution mapping of genic targeting preferences during HIV-1 integration in vitro and in vivo. Nucleic Acids Res. 49, 7330\u20137346 (2021).","journal-title":"Nucleic Acids Res."},{"key":"2611_CR35","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.chom.2022.12.002","volume":"31","author":"X Lian","year":"2023","unstructured":"Lian, X. et al. Progressive transformation of the HIV-1 reservoir cell profile over two decades of antiviral therapy. Cell Host Microbe 31, 83\u201396.e85 (2023).","journal-title":"Cell Host Microbe"},{"key":"2611_CR36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/s41586-022-05538-8","volume":"614","author":"W Sun","year":"2023","unstructured":"Sun, W. et al. Phenotypic signatures of immune selection in HIV-1 reservoir cells. Nature 614, 309\u2013317 (2023).","journal-title":"Nature"},{"key":"2611_CR37","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.cell.2021.12.011","volume":"185","author":"KB Einkauf","year":"2022","unstructured":"Einkauf, K. B. et al. Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. Cell 185, 266\u2013282.e215 (2022).","journal-title":"Cell"},{"key":"2611_CR38","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1093\/nar\/gkaa536","volume":"48","author":"G Vansant","year":"2020","unstructured":"Vansant, G. et al. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Res. 48, 7801\u20137817 (2020).","journal-title":"Nucleic Acids Res."},{"key":"2611_CR39","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest. 129, 988\u2013998 (2019).","journal-title":"J. Clin. Invest."},{"key":"2611_CR40","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature14248","volume":"518","author":"A Kundaje","year":"2015","unstructured":"Kundaje, A. et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317\u2013330 (2015).","journal-title":"Nature"},{"key":"2611_CR41","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13578-020-0374-z","volume":"10","author":"Z Sun","year":"2020","unstructured":"Sun, Z. et al. H3K36me3, message from chromatin to DNA damage repair. Cell Biosci. 10, 9 (2020).","journal-title":"Cell Biosci."},{"key":"2611_CR42","doi-asserted-by":"crossref","first-page":"e0242520","DOI":"10.1128\/JVI.02425-20","volume":"95","author":"Y Ren","year":"2021","unstructured":"Ren, Y. et al. Selective BCL-X(L) antagonists eliminate infected cells from a primary-cell model of HIV latency but not from ex vivo reservoirs. J. Virol. 95, e0242520 (2021).","journal-title":"J. Virol."},{"key":"2611_CR43","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1172\/JCI132374","volume":"130","author":"Y Ren","year":"2020","unstructured":"Ren, Y. et al. BCL-2 antagonism sensitizes cytotoxic T cell-resistant HIV reservoirs to elimination ex vivo. J. Clin. Invest. 130, 2542\u20132559 (2020).","journal-title":"J. Clin. Invest."},{"key":"2611_CR44","doi-asserted-by":"crossref","first-page":"e2218960120","DOI":"10.1073\/pnas.2218960120","volume":"120","author":"B Etemad","year":"2023","unstructured":"Etemad, B. et al. HIV post-treatment controllers have distinct immunological and virological features. Proc. Natl Acad. Sci. USA 120, e2218960120 (2023).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR45","doi-asserted-by":"crossref","first-page":"e0125422","DOI":"10.1128\/jvi.01254-22","volume":"97","author":"A Wedrychowski","year":"2023","unstructured":"Wedrychowski, A. et al. Transcriptomic signatures of human immunodeficiency virus post-treatment control. J. Virol. 97, e0125422 (2023).","journal-title":"J. Virol."},{"key":"2611_CR46","first-page":"7426","volume":"61","author":"AJ Philp","year":"2001","unstructured":"Philp, A. J. et al. The phosphatidylinositol 3\u2032-kinase p85\u03b1 gene is an oncogene in human ovarian and colon tumors. Cancer Res. 61, 7426\u20137429 (2001).","journal-title":"Cancer Res."},{"key":"2611_CR47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.ccr.2005.05.014","volume":"7","author":"Y Samuels","year":"2005","unstructured":"Samuels, Y. et al. Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7, 561\u2013573 (2005).","journal-title":"Cancer Cell"},{"key":"2611_CR48","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.3389\/fmicb.2018.02738","volume":"9","author":"S Lata","year":"2018","unstructured":"Lata, S., Mishra, R. & Banerjea, A. C. Proteasomal degradation machinery: favorite target of HIV-1 proteins. Front. Microbiol. 9, 2738 (2018).","journal-title":"Front. Microbiol."},{"key":"2611_CR49","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/sj.leu.2403400","volume":"18","author":"Y Satou","year":"2004","unstructured":"Satou, Y. et al. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro. Leukemia 18, 1357\u20131363 (2004).","journal-title":"Leukemia"},{"key":"2611_CR50","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s12985-022-01764-8","volume":"19","author":"Y Hu","year":"2022","unstructured":"Hu, Y. et al. RUNX1 inhibits the antiviral immune response against influenza A virus through attenuating type I interferon signaling. Virol. J. 19, 39 (2022).","journal-title":"Virol. J."},{"key":"2611_CR51","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature05673","volume":"446","author":"M Ono","year":"2007","unstructured":"Ono, M. et al. Foxp3 controls regulatory T-cell function by interacting with AML1\/Runx1. Nature 446, 685\u2013689 (2007).","journal-title":"Nature"},{"key":"2611_CR52","doi-asserted-by":"crossref","first-page":"107","DOI":"10.20411\/pai.v1i1.125","volume":"1","author":"NS Utay","year":"2016","unstructured":"Utay, N. S. & Douek, D. C. Interferons and HIV infection: the good, the bad, and the ugly. Pathog. Immun. 1, 107\u2013116 (2016).","journal-title":"Pathog. Immun."},{"key":"2611_CR53","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00005-015-0357-7","volume":"64","author":"A Wyczalkowska-Tomasik","year":"2016","unstructured":"Wyczalkowska-Tomasik, A., Czarkowska-Paczek, B., Zielenkiewicz, M. & Paczek, L. Inflammatory markers change with age, but do not fall beyond reported normal ranges. Arch. Immunol. Ther. Exp. 64, 249\u2013254 (2016).","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"2611_CR54","doi-asserted-by":"crossref","first-page":"6776","DOI":"10.1073\/pnas.0611244104","volume":"104","author":"A Saez-Cirion","year":"2007","unstructured":"Saez-Cirion, A. et al. HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104, 6776\u20136781 (2007).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR55","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins, D. R., Gaiha, G. D. & Walker, B. D. CD8+ T cells in HIV control, cure and prevention. Nat. Rev. Immunol. 20, 471\u2013482 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2611_CR56","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.immuni.2016.08.018","volume":"45","author":"EK Cartwright","year":"2016","unstructured":"Cartwright, E. K. et al. CD8+ lymphocytes are required for maintaining viral suppression in SIV-infected macaques treated with short-term antiretroviral therapy. Immunity 45, 656\u2013668 (2016).","journal-title":"Immunity"},{"key":"2611_CR57","doi-asserted-by":"crossref","first-page":"e57246","DOI":"10.7554\/eLife.57246","volume":"9","author":"JA Warren","year":"2020","unstructured":"Warren, J. A. et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells. eLife 9, e57246 (2020).","journal-title":"eLife"},{"key":"2611_CR58","doi-asserted-by":"crossref","first-page":"e165245","DOI":"10.1172\/JCI165245","volume":"133","author":"JA White","year":"2023","unstructured":"White, J. A. et al. Clonally expanded HIV-1 proviruses with 5\u2032-leader defects can give rise to nonsuppressible residual viremia. J. Clin. Invest. 133, e165245 (2023).","journal-title":"J. Clin. Invest."},{"key":"2611_CR59","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.immuni.2018.04.004","volume":"48","author":"H-H Kuo","year":"2018","unstructured":"Kuo, H.-H. et al. Anti-apoptotic protein BIRC5 maintains survival of HIV-1-infected CD4+ T Cells. Immunity 48, 1183\u20131194.e1185 (2018).","journal-title":"Immunity"},{"key":"2611_CR60","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1038\/s41591-021-01371-0","volume":"27","author":"SM Zekavat","year":"2021","unstructured":"Zekavat, S. M. et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat. Med. 27, 1012\u20131024 (2021).","journal-title":"Nat. Med."},{"key":"2611_CR61","doi-asserted-by":"crossref","first-page":"e0000722","DOI":"10.1128\/mbio.00007-22","volume":"13","author":"J Janssens","year":"2022","unstructured":"Janssens, J., De Wit, F., Parveen, N. & Debyser, Z. Single-Cell Imaging Shows That the Transcriptional State of the HIV-1 Provirus and Its Reactivation Potential Depend on the Integration Site. mBio 13, e0000722 (2022).","journal-title":"mBio"},{"key":"2611_CR62","doi-asserted-by":"crossref","first-page":"7801","DOI":"10.1093\/nar\/gkaa536","volume":"48","author":"G Vansant","year":"2020","unstructured":"Vansant, G. et al. The chromatin landscape at the HIV-1 provirus integration site determines viral expression. Nucleic Acids Res 48, 7801\u20137817 (2020).","journal-title":"Nucleic Acids Res"},{"key":"2611_CR63","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1172\/JCI124291","volume":"129","author":"KB Einkauf","year":"2019","unstructured":"Einkauf, K. B. et al. Intact HIV-1 proviruses accumulate at distinct chromosomal positions during prolonged antiretroviral therapy. J. Clin. Invest 129, 988\u2013998 (2019).","journal-title":"J. Clin. Invest"},{"key":"2611_CR64","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nature02399","volume":"428","author":"J Grimwood","year":"2004","unstructured":"Grimwood, J. et al. The DNA sequence and biology of human chromosome 19. Nature 428, 529\u2013535 (2004).","journal-title":"Nature"},{"key":"2611_CR65","doi-asserted-by":"crossref","unstructured":"Singh, P.K., Bedwell, G.J. & Engelman, A.N. Spatial and Genomic Correlates of HIV-1 Integration Site Targeting. Cells 11(2022).","DOI":"10.3390\/cells11040655"},{"key":"2611_CR66","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAD.0000000000003111","volume":"36","author":"SS Rout","year":"2022","unstructured":"Rout, S. S., Di, Y., Dittmer, U., Sutter, K. & Lavender, K. J. Distinct effects of treatment with two different interferon-alpha subtypes on HIV-1-associated T-cell activation and dysfunction in humanized mice. AIDS 36, 325\u2013336 (2022).","journal-title":"AIDS"},{"key":"2611_CR67","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3389\/fimmu.2017.01823","volume":"8","author":"A Soper","year":"2017","unstructured":"Soper, A. et al. Type I Interferon Responses by HIV-1 Infection: Association with Disease Progression and Control. Front Immunol. 8, 1823 (2017).","journal-title":"Front Immunol."},{"key":"2611_CR68","doi-asserted-by":"crossref","first-page":"10395","DOI":"10.1128\/JVI.00849-09","volume":"83","author":"BP Doehle","year":"2009","unstructured":"Doehle, B. P., Hladik, F., McNevin, J. P., McElrath, M. J. & Gale, M. Jr. Human immunodeficiency virus type 1 mediates global disruption of innate antiviral signaling and immune defenses within infected cells. J. Virol. 83, 10395\u201310405 (2009).","journal-title":"J. Virol."},{"key":"2611_CR69","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.chom.2015.08.009","volume":"18","author":"L Pache","year":"2015","unstructured":"Pache, L. et al. BIRC2\/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency. Cell Host Microbe 18, 345\u2013353 (2015).","journal-title":"Cell Host Microbe"},{"key":"2611_CR70","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1074\/jbc.M208672200","volume":"278","author":"J Kuai","year":"2003","unstructured":"Kuai, J. et al. Endogenous association of TRAF2, TRAF3, cIAP1, and Smac with lymphotoxin beta receptor reveals a novel mechanism of apoptosis. J. Biol. Chem. 278, 14363\u201314369 (2003).","journal-title":"J. Biol. Chem."},{"key":"2611_CR71","doi-asserted-by":"crossref","first-page":"922","DOI":"10.3389\/fimmu.2020.00922","volume":"11","author":"JG Skeate","year":"2020","unstructured":"Skeate, J. G. et al. TNFSF14: LIGHTing the Way for Effective Cancer Immunotherapy. Front Immunol. 11, 922 (2020).","journal-title":"Front Immunol."},{"key":"2611_CR72","doi-asserted-by":"crossref","first-page":"827717","DOI":"10.3389\/fcimb.2022.827717","volume":"12","author":"S Pasquereau","year":"2022","unstructured":"Pasquereau, S. & Herbein, G. CounterAKTing HIV: Toward a \u201cBlock and Clear\u201d Strategy? Front Cell Infect. Microbiol 12, 827717 (2022).","journal-title":"Front Cell Infect. Microbiol"},{"key":"2611_CR73","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.chom.2017.12.004","volume":"23","author":"Y Kim","year":"2018","unstructured":"Kim, Y., Anderson, J. L. & Lewin, S. R. Getting the \u201cKill\u201d into \u201cShock and Kill\u201d: Strategies to Eliminate Latent HIV. Cell Host Microbe 23, 14\u201326 (2018).","journal-title":"Cell Host Microbe"},{"key":"2611_CR74","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1073\/pnas.98.1.253","volume":"98","author":"TW Chun","year":"2001","unstructured":"Chun, T. W. et al. Suppression of HIV replication in the resting CD4+ T cell reservoir by autologous CD8+ T cells: implications for the development of therapeutic strategies. Proc. Natl Acad. Sci. USA 98, 253\u2013258 (2001).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR75","doi-asserted-by":"crossref","first-page":"23","DOI":"10.2174\/1570162043485077","volume":"2","author":"N Gulzar","year":"2004","unstructured":"Gulzar, N. & Copeland, K. F. CD8+ T-cells: function and response to HIV infection. Curr. HIV Res 2, 23\u201337 (2004).","journal-title":"Curr. HIV Res"},{"key":"2611_CR76","doi-asserted-by":"crossref","first-page":"e1006629","DOI":"10.1371\/journal.ppat.1006629","volume":"13","author":"AS Thomas","year":"2017","unstructured":"Thomas, A. S. et al. T-cell responses targeting HIV Nef uniquely correlate with infected cell frequencies after long-term antiretroviral therapy. PLoS Pathog. 13, e1006629 (2017).","journal-title":"PLoS Pathog."},{"key":"2611_CR77","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0022-2836(02)01305-0","volume":"326","author":"DC Lawrence","year":"2003","unstructured":"Lawrence, D. C., Stover, C. C., Noznitsky, J., Wu, Z. & Summers, M. F. Structure of the Intact Stem and Bulge of HIV-1 \u03a8-RNA Stem-Loop SL1. J. Mol. Biol. 326, 529\u2013542 (2003).","journal-title":"J. Mol. Biol."},{"key":"2611_CR78","doi-asserted-by":"crossref","first-page":"101500","DOI":"10.1016\/j.jbc.2021.101500","volume":"298","author":"S Durand","year":"2022","unstructured":"Durand, S. et al. Quantitative analysis of the formation of nucleoprotein complexes between HIV-1 Gag protein and genomic RNA using transmission electron microscopy. J. Biol. Chem. 298, 101500 (2022).","journal-title":"J. Biol. Chem."},{"key":"2611_CR79","doi-asserted-by":"crossref","first-page":"35061","DOI":"10.1074\/jbc.M114.621425","volume":"289","author":"N van Bel","year":"2014","unstructured":"van Bel, N., Das, A. T., Cornelissen, M., Abbink, T. E. & Berkhout, B. A short sequence motif in the 5' leader of the HIV-1 genome modulates extended RNA dimer formation and virus replication. J. Biol. Chem. 289, 35061\u201335074 (2014).","journal-title":"J. Biol. Chem."},{"key":"2611_CR80","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41577-019-0203-y","volume":"20","author":"NM Chapman","year":"2020","unstructured":"Chapman, N. M., Boothby, M. R. & Chi, H. Metabolic coordination of T cell quiescence and activation. Nat. Rev. Immunol. 20, 55\u201370 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"2611_CR81","doi-asserted-by":"crossref","first-page":"e1010845","DOI":"10.1371\/journal.ppat.1010845","volume":"18","author":"JA White","year":"2022","unstructured":"White, J. A. et al. Measuring the latent reservoir for HIV-1: Quantification bias in near full- length genome sequencing methods. PLoS Pathog. 18, e1010845 (2022).","journal-title":"PLoS Pathog."},{"key":"2611_CR82","doi-asserted-by":"crossref","first-page":"6441","DOI":"10.1128\/JVI.00591-06","volume":"80","author":"JR Bailey","year":"2006","unstructured":"Bailey, J. R. et al. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J. Virol. 80, 6441\u20136457 (2006).","journal-title":"J. Virol."},{"key":"2611_CR83","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.chom.2019.08.003","volume":"26","author":"MA De Scheerder","year":"2019","unstructured":"De Scheerder, M. A. et al. HIV Rebound Is Predominantly Fueled by Genetically Identical Viral Expansions from Diverse Reservoirs. Cell Host Microbe 26, 347\u2013358.e347 (2019).","journal-title":"Cell Host Microbe"},{"key":"2611_CR84","doi-asserted-by":"crossref","unstructured":"Cizmeci, D., et al. Distinct clonal evolution of B-cells in HIV controllers with neutralizing antibody breadth. Elife 10(2021).","DOI":"10.7554\/eLife.62648"},{"key":"2611_CR85","doi-asserted-by":"crossref","unstructured":"White, J.A., et al. Clonally expanded HIV-1 proviruses with 5'-Leader defects can give rise to nonsuppressible residual viremia. J Clin Invest (2023).","DOI":"10.1172\/JCI165245"},{"key":"2611_CR86","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.chembiol.2023.03.003","volume":"30","author":"J Richard","year":"2023","unstructured":"Richard, J. et al. Temsavir blocks the immunomodulatory activities of HIV-1 soluble gp120. Cell Chem. Biol. 30, 540\u2013552.e546 (2023).","journal-title":"Cell Chem. Biol."},{"key":"2611_CR87","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.0800050105","volume":"105","author":"S Palmer","year":"2008","unstructured":"Palmer, S. et al. Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc. Natl Acad. Sci. USA 105, 3879\u20133884 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"2611_CR88","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jpba.2016.01.038","volume":"122","author":"JH Zheng","year":"2016","unstructured":"Zheng, J. H. et al. Application of an intracellular assay for determination of tenofovir- diphosphate and emtricitabine-triphosphate from erythrocytes using dried blood spots. J. Pharm. Biomed. Anal. 122, 16\u201320 (2016).","journal-title":"J. Pharm. Biomed. Anal."},{"key":"2611_CR89","doi-asserted-by":"crossref","unstructured":"Tosiano, M.A., Jacobs, J.L., Shutt, K.A., Cyktor, J.C. & Mellors, J.W. A Simpler and More Sensitive Single-Copy HIV-1 RNA Assay for Quantification of Persistent HIV-1 Viremia in Individuals on Suppressive Antiretroviral Therapy. J Clin Microbiol 57(2019).","DOI":"10.1128\/JCM.01714-18"},{"key":"2611_CR90","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41586-020-2651-8","volume":"585","author":"C Jiang","year":"2020","unstructured":"Jiang, C. et al. Distinct viral reservoirs in individuals with spontaneous control of HIV-1. Nature 585, 261\u2013267 (2020).","journal-title":"Nature"},{"key":"2611_CR91","doi-asserted-by":"crossref","DOI":"10.1186\/s12859-018-2139-9","volume":"19","author":"M Cornwell","year":"2018","unstructured":"Cornwell, M. et al. VIPER: Visualization Pipeline for RNA-seq, a Snakemake workflow for efficient and complete RNA-seq analysis. BMC Bioinforma. 19, 135 (2018).","journal-title":"BMC Bioinforma."},{"key":"2611_CR92","volume":"15","author":"MI Love","year":"2014","unstructured":"Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).","journal-title":"Genome Biol."},{"key":"2611_CR93","unstructured":"Korotkevich, G., et al. Fast gene set enrichment analysis. bioRxiv, 060012 (2021)."},{"key":"2611_CR94","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.1256304","volume":"345","author":"TA Wagner","year":"2014","unstructured":"Wagner, T. A. et al. Proliferation of cells with HIV integrated into cancer genes contributes to persistent infection. Science 345, 570\u2013573 (2014).","journal-title":"Science"},{"key":"2611_CR95","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/bioinformatics\/bty712","volume":"35","author":"TR Sibley","year":"2019","unstructured":"Sibley, T. R., Silberman, E. J. & Mullins, J. I. ISDB: a database toolkit for storing and analyzing viral integration site data. Bioinformatics 35, 1073\u20131075 (2019).","journal-title":"Bioinformatics"},{"key":"2611_CR96","unstructured":"Llano, A., Cede\u00f1o, S., Arrieta, S. & Brander, C. The 2019 Optimal HIV CTL epitopes update : Growing diversity in epitope length and HLA restriction. Los Alamos National Laboratory (2019)."},{"key":"2611_CR97","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2009","unstructured":"Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139\u2013140 (2009).","journal-title":"Bioinformatics"},{"key":"2611_CR98","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1126\/science.aav5095","volume":"364","author":"GD Gaiha","year":"2019","unstructured":"Gaiha, G. D. et al. Structural topology defines protective CD8(+) T cell epitopes in the HIV proteome. Science 364, 480\u2013484 (2019).","journal-title":"Science"},{"key":"2611_CR99","doi-asserted-by":"crossref","first-page":"103175","DOI":"10.1016\/j.ebiom.2020.103175","volume":"63","author":"TM Garcia-Bates","year":"2021","unstructured":"Garcia-Bates, T. M. et al. Dendritic cells focus CTL responses toward highly conserved and topologically important HIV-1 epitopes. EBioMedicine 63, 103175 (2021).","journal-title":"EBioMedicine"},{"key":"2611_CR100","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.1232685","volume":"340","author":"R Apps","year":"2013","unstructured":"Apps, R. et al. Influence of HLA-C expression level on HIV control. Science 340, 87\u201391 (2013).","journal-title":"Science"},{"key":"2611_CR101","doi-asserted-by":"crossref","first-page":"13202","DOI":"10.1128\/JVI.01998-12","volume":"86","author":"JM Carlson","year":"2012","unstructured":"Carlson, J. M. et al. Correlates of Protective Cellular Immunity Revealed by Analysis of Population-Level Immune Escape Pathways in HIV-1. J. Virol. 86, 13202\u201313216 (2012).","journal-title":"J. Virol."},{"key":"2611_CR102","doi-asserted-by":"crossref","unstructured":"Warren, J.A., et al. The HIV-1 latent reservoir is largely sensitive to circulating T cells. Elife 9(2020).","DOI":"10.7554\/eLife.57246"},{"key":"2611_CR103","doi-asserted-by":"crossref","first-page":"e1003398","DOI":"10.1371\/journal.ppat.1003398","volume":"9","author":"GM Laird","year":"2013","unstructured":"Laird, G. M. et al. Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog. 9, e1003398 (2013).","journal-title":"PLoS Pathog."}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02611-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02611-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,13]],"date-time":"2023-12-13T11:10:41Z","timestamp":1702465841000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-023-02611-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,13]]},"references-count":103,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["2611"],"URL":"https:\/\/doi.org\/10.1038\/s41591-023-02611-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2023.03.30.23287124","asserted-by":"object"}]},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,13]]},"assertion":[{"value":"7 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.R.C.M. has received funding from Gilead Sciences for investigator-initiated research paid to his institution. P.L.A. has received past consulting fees from Gilead, ViiV and Merck and research funding from Gilead paid to institution, unrelated to this work. G.D.G. has received grant funding from Merck. J.Z.L. has consulted for Abbvie and received grant funding from Merck. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}